GILD GILEAD SCIENCES INC revenue, earnings and financials

For the quarter ended June 30, 2026, GILEAD SCIENCES INC reported revenue of $7.80B (up 10.2% from a year earlier), net income of −$10.5B and diluted EPS of −$8.45; over the last four quarters revenue was $30.5B and net income −$3.24B; for the fiscal year ended December 2025 revenue was $29.4B, up 2.4% on the year before.

GILD annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $29.4B, gross profit n/a, operating income $10.0B, net income $8.51B (margin 28.9%), EPS $6.78
• Fiscal year ended Dec 2024: revenue $28.8B, gross profit n/a, operating income $1.66B, net income $480M (margin 1.7%), EPS $0.38
• Fiscal year ended Dec 2023: revenue $27.1B, gross profit n/a, operating income $7.61B, net income $5.67B (margin 20.9%), EPS $4.50
• Fiscal year ended Dec 2022: revenue $27.3B, gross profit n/a, operating income $7.33B, net income $4.59B (margin 16.8%), EPS $3.64
• Fiscal year ended Dec 2021: revenue $27.3B, gross profit n/a, operating income $9.92B, net income $6.23B (margin 22.8%), EPS $4.93

GILD quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $7.80B (up 10.2% year over year), net income −$10.5B, EPS −$8.45
• Quarter ended Mar 31, 2026: revenue $6.96B (up 4.4% year over year), net income $2.02B, EPS $1.61
• Quarter ended Dec 31, 2025 (from the annual report): revenue $7.93B (up 4.7% year over year), net income $2.18B, EPS $1.75
• Quarter ended Sep 30, 2025: revenue $7.77B (up 3.0% year over year), net income $3.05B, EPS $2.43
• Quarter ended Jun 30, 2025: revenue $7.08B (up 1.8% year over year), net income $1.96B, EPS $1.56
• Quarter ended Mar 31, 2025: revenue $6.67B (down 0.3% year over year), net income $1.32B, EPS $1.04
• Quarter ended Dec 31, 2024 (from the annual report): revenue $7.57B (up 6.4% year over year), net income $1.78B, EPS $1.43
• Quarter ended Sep 30, 2024: revenue $7.55B (up 7.0% year over year), net income $1.25B, EPS $1.00
• Quarter ended Jun 30, 2024: revenue $6.95B (up 5.4% year over year), net income $1.61B, EPS $1.29
• Quarter ended Mar 31, 2024: revenue $6.69B (up 5.3% year over year), net income −$4.17B, EPS −$3.34
• Quarter ended Dec 31, 2023 (from the annual report): revenue $7.11B (down 3.7% year over year), net income $1.43B, EPS $1.14
• Quarter ended Sep 30, 2023: revenue $7.05B (up 0.1% year over year), net income $2.18B, EPS $1.73
• Quarter ended Jun 30, 2023: revenue $6.60B (up 5.4% year over year), net income $1.05B, EPS $0.83
• Quarter ended Mar 31, 2023: revenue $6.35B (down 3.6% year over year), net income $1.01B, EPS $0.80
• Quarter ended Dec 31, 2022 (from the annual report): revenue $7.39B (up 2.0% year over year), net income $1.64B, EPS $1.29
• Quarter ended Sep 30, 2022: revenue $7.04B (down 5.1% year over year), net income $1.79B, EPS $1.42
• Quarter ended Jun 30, 2022: revenue $6.26B (up 0.7% year over year), net income $1.14B, EPS $0.91
• Quarter ended Mar 31, 2022: revenue $6.59B (up 2.6% year over year), net income $19.0M, EPS $0.02
• Quarter ended Dec 31, 2021 (from the annual report): revenue $7.24B, net income $382M, EPS $0.30
• Quarter ended Sep 30, 2021: revenue $7.42B, net income $2.59B, EPS $2.05

GILD cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $10.0B, share buybacks $1.92B, dividends $3.16 per share
• Fiscal year ended Dec 2024: operating cash flow $10.8B, share buybacks $1.15B, dividends $3.08 per share
• Fiscal year ended Dec 2023: operating cash flow $8.01B, share buybacks $1.00B, dividends $3.00 per share
• Fiscal year ended Dec 2022: operating cash flow $9.07B, share buybacks $1.40B, dividends $2.92 per share
• Fiscal year ended Dec 2021: operating cash flow $11.4B, share buybacks $546M, dividends $2.84 per share

GILD balance sheet

• Jun 30, 2026: cash n/a, total assets $49.4B, total liabilities n/a, shareholders' equity $11.8B, long-term debt $23.8B
• Mar 31, 2026: cash n/a, total assets $56.3B, total liabilities n/a, shareholders' equity $23.5B, long-term debt $20.9B
• Dec 31, 2025: cash n/a, total assets $59.0B, total liabilities n/a, shareholders' equity $22.7B, long-term debt $22.1B
• Sep 30, 2025: cash n/a, total assets $58.5B, total liabilities n/a, shareholders' equity $21.5B, long-term debt $22.1B
• Jun 30, 2025: cash n/a, total assets $55.7B, total liabilities n/a, shareholders' equity $19.7B, long-term debt $22.1B
• Mar 31, 2025: cash n/a, total assets $56.4B, total liabilities n/a, shareholders' equity $19.2B, long-term debt $22.1B
• Dec 31, 2024: cash n/a, total assets $59.0B, total liabilities n/a, shareholders' equity $19.3B, long-term debt $24.9B
• Sep 30, 2024: cash n/a, total assets $54.5B, total liabilities n/a, shareholders' equity $18.5B, long-term debt $21.4B

What is GILD's revenue?

GILEAD SCIENCES INC reported $30.5B of revenue over its last four quarters, through June 30, 2026.

Is GILD profitable?

No. GILEAD SCIENCES INC lost $3.24B over the last four quarters.

What is GILD's EPS?

Diluted earnings per share over the last four quarters were −$2.66; −$8.45 in the latest quarter.

Does GILD pay a dividend?

GILEAD SCIENCES INC paid $3.16 per share in dividends in the fiscal year ended December 2025.

GILD ownership and insider trades · All stocks